Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Solar storms have influenced our history – an environmental historian explains how they could also threaten our future- Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
- The Way to Business: Startup Illustrations Learned
- Antimatter took to the road for the very first time. Here’s why it matters
- Can scientists detect life without knowing what it looks like? Research using machine learning offers a new way
- Heat Wave Fuels Massive Wildfire In Australia
- The Most Compelling Innovation Developments Somewhat recently
- Ifo: Job cuts in Germany slowing but not enough for a turnaround
- Tech Patterns 2023: 12 Advancements to Keep an eye Out For
